Diseases of the Nervous System, Phase IIB

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH)

Volunteers
Health Professionals

What is the purpose of this trial?

Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.

Trial with
National Institute of Neurological Disorders and Stroke (NINDS)
Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Erin Longbrake

erin.longbrake@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Erin Longbrake, MD/PhD
Associate Professor of Neurology; Director, Clinical Research, Neuroimmunology; Director, Fellowship Program, Multiple Sclerosis & Other Inflammatory Brain Disease

Sub-Investigators

Last Updated
02/02/2024
Study HIC
#2000030521